Literature DB >> 30135583

A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.

Roshni Roy Chowdhury1,2, Francesco Vallania3,4, Qianting Yang5, Cesar Joel Lopez Angel1,2, Fatoumatta Darboe6,7, Adam Penn-Nicholson6,7, Virginie Rozot6,7, Elisa Nemes6,7, Stephanus T Malherbe8, Katharina Ronacher8,9,10, Gerhard Walzl8,9, Willem Hanekom6,11, Mark M Davis1,2,3,12, Jill Winter13, Xinchun Chen14, Thomas J Scriba6,7, Purvesh Khatri15,16,17, Yueh-Hsiu Chien18,19.   

Abstract

Most infections with Mycobacterium tuberculosis (Mtb) manifest as a clinically asymptomatic, contained state, known as latent tuberculosis infection, that affects approximately one-quarter of the global population1. Although fewer than one in ten individuals eventually progress to active disease2, tuberculosis is a leading cause of death from infectious disease worldwide3. Despite intense efforts, immune factors that influence the infection outcomes remain poorly defined. Here we used integrated analyses of multiple cohorts to identify stage-specific host responses to Mtb infection. First, using high-dimensional mass cytometry analyses and functional assays of a cohort of South African adolescents, we show that latent tuberculosis is associated with enhanced cytotoxic responses, which are mostly mediated by CD16 (also known as FcγRIIIa) and natural killer cells, and continuous inflammation coupled with immune deviations in both T and B cell compartments. Next, using cell-type deconvolution of transcriptomic data from several cohorts of different ages, genetic backgrounds, geographical locations and infection stages, we show that although deviations in peripheral B and T cell compartments generally start at latency, they are heterogeneous across cohorts. However, an increase in the abundance of circulating natural killer cells in tuberculosis latency, with a corresponding decrease during active disease and a return to baseline levels upon clinical cure are features that are common to all cohorts. Furthermore, by analysing three longitudinal cohorts, we find that changes in peripheral levels of natural killer cells can inform disease progression and treatment responses, and inversely correlate with the inflammatory state of the lungs of patients with active tuberculosis. Together, our findings offer crucial insights into the underlying pathophysiology of tuberculosis latency, and identify factors that may influence infection outcomes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30135583      PMCID: PMC6414221          DOI: 10.1038/s41586-018-0439-x

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  64 in total

1.  Computational and Systems Immunology: A Student's Perspective.

Authors:  Zinaida Good; Jacob Glanville; Marvin H Gee; Mark M Davis; Purvesh Khatri
Journal:  Trends Immunol       Date:  2019-07-06       Impact factor: 16.687

Review 2.  Targeting innate immunity for tuberculosis vaccination.

Authors:  Shabaana A Khader; Maziar Divangahi; Willem Hanekom; Philip C Hill; Markus Maeurer; Karen W Makar; Katrin D Mayer-Barber; Musa M Mhlanga; Elisa Nemes; Larry S Schlesinger; Reinout van Crevel; Raman (Krishna) Vankayalapati; Ramnik J Xavier; Mihai G Netea
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

3.  Distinct Features of Human Myeloid Cell Cytokine Response Profiles Identify Neutrophil Activation by Cytokines as a Prognostic Feature during Tuberculosis and Cancer.

Authors:  Joseph C Devlin; Erin E Zwack; Mei San Tang; Zhi Li; David Fenyo; Victor J Torres; Kelly V Ruggles; P'ng Loke
Journal:  J Immunol       Date:  2020-04-29       Impact factor: 5.422

Review 4.  The science and medicine of human immunology.

Authors:  Bali Pulendran; Mark M Davis
Journal:  Science       Date:  2020-09-25       Impact factor: 47.728

5.  Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmette-Guérin Vaccination to Improve Antiviral Antibody Responses.

Authors:  Tony W Ng; Ariel S Wirchnianski; Anna Z Wec; J Maximilian Fels; Christopher T Johndrow; Kevin O Saunders; Hua-Xin Liao; John Chan; William R Jacobs; Kartik Chandran; Steven A Porcelli
Journal:  J Immunol       Date:  2020-06-08       Impact factor: 5.422

Review 6.  Tuberculosis Vaccine Development: Progress in Clinical Evaluation.

Authors:  Suraj B Sable; James E Posey; Thomas J Scriba
Journal:  Clin Microbiol Rev       Date:  2019-10-30       Impact factor: 26.132

7.  New Perspectives in Latent Tuberculosis Infection.

Authors:  Miguel Arias-Guillén; Patricio Escalante; Juan José Palacios Gutiérrez
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2019-08-09

Review 8.  The knowns and unknowns of latent Mycobacterium tuberculosis infection.

Authors:  W Henry Boom; Ulrich E Schaible; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

9.  An immune-cell signature of bacterial sepsis.

Authors:  Miguel Reyes; Michael R Filbin; Roby P Bhattacharyya; Kianna Billman; Thomas Eisenhaure; Deborah T Hung; Bruce D Levy; Rebecca M Baron; Paul C Blainey; Marcia B Goldberg; Nir Hacohen
Journal:  Nat Med       Date:  2020-02-17       Impact factor: 53.440

10.  Multimodally profiling memory T cells from a tuberculosis cohort identifies cell state associations with demographics, environment and disease.

Authors:  Aparna Nathan; Jessica I Beynor; Yuriy Baglaenko; Sara Suliman; Kazuyoshi Ishigaki; Samira Asgari; Chuan-Chin Huang; Yang Luo; Zibiao Zhang; Kattya Lopez; Cecilia S Lindestam Arlehamn; Joel D Ernst; Judith Jimenez; Roger I Calderón; Leonid Lecca; Ildiko Van Rhijn; D Branch Moody; Megan B Murray; Soumya Raychaudhuri
Journal:  Nat Immunol       Date:  2021-05-24       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.